CompanyGraph
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $23.66M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.69×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations2 currently firing — 2
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
17.52MGBP23.66M · vs all stocks (USD)
Revenue (TTM)
7.28MGBP9.83M · vs all stocks (USD)
Profit Margin
-24.98%vs Biotechnology peers
Beta
0.1140xvs all stocks
52-Week Change
-31.25%vs all stocks
Market Capitalization
17.52MGBP23.66M · vs all stocks (USD)
Enterprise Value
6.30MGBP8.50M · vs all stocks (USD)
Forward P/E
-6.15xvs Biotechnology peers
Price to Sales (TTM)
2.41xvs Biotechnology peers
Price to Book (MRQ)
0.6897xvs Biotechnology peers
Enterprise to Revenue
0.8660xvs Biotechnology peers
Enterprise to EBITDA
-2.36xvs Biotechnology peers
Profit Margin
-24.98%vs Biotechnology peers
Operating Margin
-31.43%vs Biotechnology peers
Return on Assets (TTM)
-13.24%vs Biotechnology peers
Return on Equity (TTM)
-15.79%vs Biotechnology peers
Revenue (TTM)
7.28MGBP9.83M · vs all stocks (USD)
Revenue per Share (TTM)
0.0780GBPUpdated Aug 4, 2026Quarterly Revenue Growth
23.10%vs Biotechnology peers
Gross Profit (TTM)
3.69MGBP4.99M · vs all stocks (USD)
EBITDA (TTM)
-2.67MGBP-3.60M · vs all stocks (USD)
Net Income (TTM)
-1.82MGBP-2.45M · vs all stocks (USD)
Operating Cash Flow (TTM)
-2.15MGBP-2.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.18MGBP-4.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 4, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
6.53MGBPFY2025 · Sep 30, 2025Cost of Goods Sold
3.35MGBPFY2025 · Sep 30, 2025Gross Profit
3.18MGBPFY2025 · Sep 30, 2025Operating Income
-2.52MGBP-3.40M · vs all stocks (USD)
Pre-tax Income
-2.45MGBPFY2025 · Sep 30, 2025Income Tax Expense
-798.00KGBPFY2025 · Sep 30, 2025Net Income
-1.65MGBPFY2025 · Sep 30, 2025EBIT
-2.43MGBPFY2025 · Sep 30, 2025EBITDA (Income Statement)
-2.02MGBPFY2025 · Sep 30, 2025Research & Development
1.33MGBPFY2025 · Sep 30, 2025Selling, General & Administrative
4.16MGBPFY2025 · Sep 30, 2025Non-operating Interest Income
121.00KGBPFY2025 · Sep 30, 2025Non-operating Interest Expense
16.00KGBPFY2025 · Sep 30, 2025Net Income from Continuing Operations
-1.65MGBPFY2025 · Sep 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Sep 30, 2025Operating Cash Flow
-1.27MGBPFY2025 · Sep 30, 2025Free Cash Flow
-1.32MGBPFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
3.54MGBPFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-1.65MGBPFY2025 · Sep 30, 2025Stock-based Compensation
227.00KGBPFY2025 · Sep 30, 2025Other Non-cash Items
-105.00KGBPFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
258.00KGBPFY2025 · Sep 30, 2025Capital Expenditures
-51.00KGBPFY2025 · Sep 30, 2025Net Intangibles (CF)
-819.00KGBPFY2025 · Sep 30, 2025Net Investing Cash Flow
-51.00KGBPFY2025 · Sep 30, 2025Net Financing Cash Flow
3.70MGBPFY2025 · Sep 30, 2025Shares Outstanding
92.67MSharesUpdated Aug 4, 2026Float Shares
40.54MSharesUpdated Aug 4, 2026% Held by Insiders
4.89%vs all stocks
% Held by Institutions
82.55%vs all stocks
Total Cash (MRQ)
1.68MGBP2.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0180GBPUpdated Aug 4, 2026Total Debt (MRQ)
559.00KGBP754.95K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0522xvs Biotechnology peers
Current Ratio (MRQ)
2.83xvs Biotechnology peers
Book Value per Share (MRQ)
0.1160GBPUpdated Aug 4, 2026Total Assets
13.84MGBP18.69M · vs all stocks (USD)
Total Current Assets
6.23MGBPFY2025 · Sep 30, 2025Total Liabilities
2.10MGBPFY2025 · Sep 30, 2025Total Non-current Assets
7.61MGBPFY2025 · Sep 30, 2025Total Non-current Liabilities
45.00KGBPFY2025 · Sep 30, 2025Total Current Liabilities
2.06MGBPFY2025 · Sep 30, 2025Cash & Cash Equivalents
3.54MGBPFY2025 · Sep 30, 2025Accounts Receivable
1.46MGBPFY2025 · Sep 30, 2025Accounts Payable
75.00KGBPFY2025 · Sep 30, 2025Short-term Debt
149.00KGBPFY2025 · Sep 30, 2025Long-term Debt
30.00KGBPFY2025 · Sep 30, 2025Common Stock (Book)
927.00KGBPFY2025 · Sep 30, 2025Retained Earnings
-10.78MGBPFY2025 · Sep 30, 2025Total Shareholders' Equity
11.74MGBP15.85M · vs all stocks (USD)
52-Week Low
6.26GBXUpdated Aug 4, 202652-Week High
15.00GBXUpdated Aug 4, 202652-Week Change
-31.25%vs all stocks
Beta
0.1140xvs all stocks
50-Day MA
8.55GBXUpdated Aug 4, 2026200-Day MA
9.25GBXUpdated Aug 4, 2026Avg 10-Day Volume
21.13KSharesUpdated Aug 4, 2026Avg 30-Day Volume
59.09KSharesUpdated Aug 4, 2026Diluted EPS (TTM)
-0.0200GBPUpdated Aug 4, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.69×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.69Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Most companies in its industry are production businesses; this one is a sense-making businessSignificant
Industry peers: 502Share on the common pattern %: 98.00
Financial Health
Altman Z-Score 4.16: safe zoneNotable
Altman Z-Score: 4.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $23.66M, lower than 95% of all stocks globallySignificant
Market cap (USD): 23,658,506.966Global P5: 269,387,740.27
Revenue is $9.83M, lower than 95% of all stocks globallySignificant
Revenue (USD): 9,825,105.75Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Fusion Antibodies Ltd.
Tier 1SenseMakingApproval-Gated PipelineProduction
Hvivo Plc
Tier 1SenseMakingApproval-Gated PipelineProductionRule
Evotec SE
Tier 1SenseMakingApproval-Gated PipelineInterfaceProduction
Fortrea Holdings Inc.
Tier 1SenseMakingApproval-Gated PipelineFlowInterface
Shanghai Medicilon Inc.
Tier 1SenseMakingApproval-Gated PipelineProduction
Caris Life Sciences, Inc.
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
4Sight Holdings Ltd.
Tier 3SenseMakingExpertise LeverageProductionFlow
Ondo Insurtech Plc
Tier 3SenseMakingThroughput-Bound ConversionProductionInterface
Tondo Smart Ltd.
Tier 3SenseMakingExpertise LeverageProduction
Solvonis Therapeutics plc
Tier 3SenseMakingThroughput-Bound ConversionProductionRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Doximity Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquitySharp Decline With Volume And Volatility Expansion
Hexing Electrical Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquitySharp Decline With Volume And Volatility Expansion
Shenzhen Bestek Technology Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquitySharp Decline With Volume And Volatility Expansion